Human leukocyte antigen (HLA) class II haplotypes are established risk factors in type 1 diabetes (T1D). The heterozygous DQ2/8 genotype confers the highest risk, whereas the DQ6/8 genotype is protective. We hypothesized that DQ2/8 transmolecules composed of a and b chains from DQ2 and DQ8 express unique b-cell epitopes, whereas DQ6 may interfere with peptide binding to DQ8. Here we show that a single insulin epitope (InsB13-21) within the T1D prototype antigenic InsB6-22 peptide can bind to both cis-and trans-dimers, although these molecules display different peptide binding patterns. DQ6 binds a distinct insulin epitope (InsB6-14) . The phenotype of DQ8-restricted T cells from a T1D patient changed from proinflammatory to anti-inflammatory in the presence of DQ6. Our data provide new insights into both susceptible and protective mechanism of DQ, where protecting HLA molecules bind autoantigens in a different (competing) binding register leading to 'epitope stealing', thereby inducing a regulatory, rather than a pathogenic immune response.
Introduction
Type 1 diabetes mellitus (T1D) is an autoimmune disease characterized by T-cell-mediated destruction of the insulin-producing islet b-cells. 1 The disease process involves autoreactive T cells to various islet antigens such as insulin, 2 insulin secretory granules and islet cells, IA-2 and GAD65. The main hereditary elements of the disease in human beings are the human leukocyte antigen (HLA) class II loci (HLA-DQ and HLA-DR), 3, 4 whereas regulatory regions of the insulin gene called INSVNTR are the distant second genetic element of importance (also termed, respectively, as IDDM1 and IDDM2). A number of other genetic regions contribute to susceptibility in a smaller order of magnitude, including the C1858T single-nucleotide polymorphism in the PTPN22 gene (the R620W variant) and a haplotype of single-nucleotide polymorphisms in the CTLA-4 region. [5] [6] [7] Although the mechanisms of HLA-associated genetic risk with disease remain unknown, it is tempting to speculate that they involve the functional consequences of HLA molecules in antigen presentation to islet autoreactive T cells and/or their canonical role in thymic selection and shaping of the T-cell repertoire. The major histocompatibility complex (MHC) class II loci HLA-DQ and HLA-DR are in strong linkage disequilibrium and form haplotypes. The haplotypes DQB1*0302-DQA1*0301-DRB1*04 (DQ8DR4) and DQB1*0201-DQA1*0501-DRB1*0301 (DQ2DR17) are considered high-risk haplotypes, 8, 9 whereas DQB1*0602-DQA1*0102-DRB1*15 (DQ6DR15) is considered to be dominantly protective. 10, 11 Individuals heterozygous for DR4DQ8 and DR17DQ2 carry the highest odds ratio for disease, even much higher than the sum of the odds ratios of homozygous DR4DQ8 and DR17DQ2 individuals. Four different HLA-DQ molecules can be formed by the DQ8DR4/DQ2DR17 haplotypes; besides the two HLA-DQ molecules in the cis-configuration (DQA1*0501-DQB1*0201 and DQA1*0301-DQB1*0302) and two additional molecules in the trans-configuration (DQA1*0501-DQB1*0302 and DQA1*0301-DQB1*0201) can be formed. It has been suggested by geneticepidemiological studies that the DQA1*0501-DQB1*0302 trans-dimer is responsible for the increased odds ratio in heterozygous individuals. 12, 13 Intriguingly, as DQ6/8 trans-dimer formation is not possible, DQ6/8 heterozygous individuals only express the respective cis-dimers. 14, 15 Biopsies taken from newly diagnosed patients to obtain autoreactive T cells from the proximal pancreatic lymph nodes are a rarity, and little is known of insulinspecific T cells in human beings. Both proinflammatory and regulatory insulin-reactive T cells have been identified in T1D patients and healthy control subjects who were HLA class II restricted. [16] [17] [18] [19] [20] However, few detailed data exist on insulin-specific T-cell clones, which are derived from new-onset T1D patients, and epitopes of insulin-reactive T cells and their cytokine profiles have not been investigated in the context of susceptibility and protective DQ alleles. 21, 22 To gain a better understanding of the disease process, we hypothesize that DQ molecules composed of a and b chains from both the DQ2 and DQ8 haplotypes express unique b-cell epitopes, whereas DQ6 binding may interfere with peptide binding to DQ8. To explore this hypothesis, we first investigated the peptide-binding motifs within the highly antigenic insulin B6-22 region (InsB6-22) for the HLA-DQ cis-and trans-dimers. To do so, we simulated the structures of HLA-DQ molecules in both cis-and trans-configuration based on the known crystal structures of the two HLA-DQ2 and HLA-DQ8 molecules in the cis-configuration. 23, 24 From these structures, the respective peptide-binding motifs for the HLA-DQ trans-dimers were deduced and the possible complexes of these four HLA-DQ cis-and trans-molecules with peptides from the InsB6-22 region were determined. Second, to verify the peptide-binding motifs, we tested binding of insulin peptides to T1D susceptibility conferring HLA-DQ2, HLA-DQ8 and HLA-DQ2/8 molecules and the dominantly protective HLA-DQ6 molecule, by comparing HLA-DQ homozygous cell lines with heterozygous cell lines (B lymphoblastoid cell lines (BLCL)), based on the assumption that the distribution of the different HLA-DQ2 and HLA-DQ8 cis-and transmolecules on the heterozygous cell surface would be equal. To verify specificity of peptide binding to the BLCL, we genetically engineered cells selectively expressing one of the cis-or trans-dimers. Third, we cloned HLA-DQ8-restricted CD4 þ T cells specific for insulin B chain from an HLA-DQ8 homozygous T1D patient. Proliferation and cytokine profiles were established against insulin in the presence of a panel of antigenpresenting cells (APCs) of different HLA-DQ genotypes.
Results
Binding of DQ-specific peptides to DQ homozygous versus heterozygous cell lines To test whether DQ2-or DQ8-specific peptides can also bind to the trans-molecules that can be expressed by the heterozygous DQ2/DQ8 genotype, we studied peptide binding to different DQ-expressing BLCL. We performed binding experiments using peptides specific for HLA-DQ2 (EPRAP) or HLA-DQ8 (Syndecan and Thymosin b4). In a heterozygous cell line DQA1*0501/0301-DQB1*0201/0302 (HLA-DQ2/8), four different DQA1-DQB1 molecules can be expressed on the cell surface. Until now, there has been no evidence to suggest that one of the DQA1-DQB1 combinations is preferentially expressed on the cell surface of a heterozygous DQ2/8-expressing cell line compared with the other DQ combinations. Therefore, we assumed that each of the DQA1-DQB1 combinations would provide a quarter of the DQ molecules expressed on the cell surface of a heterozygous HLA-DQ2/8 cell line. Using the same number of homozygous DQ2/2 or DQ8/8 cells and heterozygous DQ2/8 cells, one can expect 25% of the binding counts in the heterozygous cells compared with the homozygous cell lines, provided that the peptide in question only binds to DQ2 and not to any of the other three DQ molecules. Indeed, this proved exactly the result of the peptide EPRAP binding to DQ2, but not to DQ8, or either of the two trans-dimers (Figure 1 ). To establish whether heterozygous DQ2/8 cells express one of the trans-dimers, binding of EPRAP to a heterozygous DQ2/8 BLCL was investigated. The relative binding of EPRAP to DQ2/8 was 25% compared to DQ2/2, indicating that EPRAP did not bind any of the transdimers. If, in addition to one of the cis-dimers, also one or two of the trans-dimers was also capable of binding the peptide, the relative peptide binding would be higher than the expected 25%.
Both Syndecan and Thymosin b4 bound DQ8 and not to DQ2 (Figure 1 ). The percentage of DQ binding was approximately 50% for both peptides for the heterozygous DQ2/8 BLCL compared with binding to DQ8 alone, implying Syndecan/Thymosin b4 peptide binding to DQ2/8 to be attributed to DQ8 cis-dimers (core nonamers for Syndecan: EDVVGPGQE and for Thymosin b4: DKPDMAEIE) as well as one of the two DQ transdimers, specifically DQ2trans (core nonamers for Syndecan: LPDDEDVVG and EDVVGPGQE, and for Thymosin b4: DKPDMAEIE).
Binding of insulin B-chain peptides to DQ homozygous and heterozygous cell lines Binding of the InsB6-22 and the InsB9-23 peptides was also examined in the whole-cell binding assay. Both InsB6-22 and InsB9-23 displayed binding to the HLA class II-deficient BLCL (721.82) compared with binding of the previously described peptides to this cell line ( Figure 2 ). This may be explained by the nonspecific adhesive properties and poorer solubility of both insulin peptides. Nonetheless, both InsB6-22 and InsB9-23 bound to both DQ2 and DQ8. Interestingly, when the peptide binding at 10 mM for the homozygous DQ8/8 BLCL was set at 100%, both peptides bound approximately 75% of the maximum to the heterozygous DQ2/8 BLCL. The relative binding of both insulin peptides to a 1:1 mixture of DQ2 þ DQ8, which express only the cisdimers, was 50%. This suggests that the observed binding in DQ2/8 heterozygotes is the result of binding to one cis-molecule and both trans-molecules expressed on the heterozygous DQ2/8 cell line, if the affinity of all four HLA-DQ molecules for the insulin peptides is identical. If the affinity is less compared with DQ8cis, as shown by binding studies (see below), then the results are consistent with the epitope binding to all four DQ molecules, in identical or different registers.
Homology modeling of the HLA-DQ-insulin peptide complex To study the interactions of the insulin peptide with the two DQ trans-molecules in detail, the corresponding complexes of DQ8-InsB13-21 and DQ2-InsB13-21 were modeled. The first complex (Supplementary Figure 1) is a direct rendition of the crystal structure of the DQ8-InsB13-21 complex as reported earlier. 25 For orientation purposes, MHC II residues interacting with peptide as well as certain T-cell receptor (TCR) contact residues are shown as evidenced from two human MHC class IIpeptide-TCR complexes, where the same TCR molecule interacts with an identical microbial peptide in identical registers in two slightly different human MHC class II molecules (DR1 and DR4). 26, 27 All DQA1*0301-bearing molecules (that is, DQ8cis and DQ2trans) have an intensely positively charged region in the vicinity of a48-54, with three Arg residues on the surface (Arg49, Arg50 and Arg53) and another one (Arg52) at the bottom of pocket 1. It is apparent that these three arginines on the surface of pocket 1 would contribute vastly to the attraction of a negatively charged p1 acidic residue that HLA-DQ8 homozygosity and heterozygosity in type 1 diabetes P Eerligh et al would eventually be anchored and detained tightly via these interactions.
Homology modeling and inspection of the respective pockets of each of the two HLA-DQ2/8 trans-molecules defined binding preferences that were compared with the preferences of DQ2cis and DQ8cis, as determined by native and anchor-substituted peptide binding and verified by crystallography ( Table 1 ). The physicochemical characteristics of the five binding pockets are as follows:
Pocket 1: The residues accepted are determined primarily by the character of the residues participating from the a-chain, as the b-chain residues in pocket 1 of all four molecules are the same (Leu85, Glu86, Thr89, Thr90) and in very similar orientations. 25 Thus, DQA1*0301-DQB1*0201 accepts acidic residues at this pocket because of a52Arg and a24His, whereas it can also accommodate large aliphatic and aromatic residues. By contrast, DQA1*0501-DQB1*0302 accommodates aromatic and aliphatic residues at this pocket, as well as Asn, Gln and Glu, but not Asp.
Pocket 4: constitutes exclusively of residues from the b-chain; therefore, the preferences there essentially reflect the preferences seen with DQ8cis and DQ2cis. Specifically, DQA1*0301-DQB1*0201 has a preference for acidic residues, and secondarily for aliphatic and Phe/Tyr. This is because the pocket is spacious and has b70Arg and b74Ala (Supplementary Table 1 ), favoring the formation of a salt bridge between the former residue and an acidic anchor at p4. Likewise, DQA1*0501-DQB1*0302 accepts aliphatic residues as well as Phe/Tyr. Acidic residues are only weakly accepted because of b74Glu, and certain polar residues are accepted with difficulty.
Pocket 6: is mostly composed of residues from the a-chain in all four molecules, yet the residue at b30 also influences the selection of the respective anchor residue. DQB1*0201, 0202, 0203 and 0204 are the only DQB molecules with a Ser residue at b30 and an Ile residue at b37. All other known DQB molecules have His/Tyr at b30 and Tyr (except DQB*0601) at b37. 32 Because of the b30Ser, the DQ2 cis-and trans-molecules accept, besides small aliphatic residues, acidic ones as well. By contrast, DQ8cis and -trans accept only small aliphatic residues in this pocket. Actually, the crystal structure of DQ2cis shows b71Lys participating in this pocket and facilitating, via water-mediated hydrogen bonds, the anchoring of an acidic residue.
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DQ2cis and -trans are among the few molecules that have a distinct preference for pocket 7: acidic, aliphatic and aromatic, but no basic residues. This is attributed to the presence of b70Arg/b71Lys, unique only to DQB1*0201/0202/0203 rendering the surface electrostatic potential of such proteins in pockets 4 and 7 very positive, attracting thus negatively charged anchor residues of the antigenic peptide. No apparent particular preference for DQ8cis or -trans could be identified at p7. Pocket 9 has a preference for acidic residues in both DQ8cis and -trans, whereas DQ2cis and -trans accept primarily aromatic residues here, and secondarily Glu and aliphatic residues. All four DQ2/8 cis-and transmolecules have Ala instead of the Asp residue at b57, thus the crucial salt bridge between this residue and invariant a76Arg is missing. Therefore, all these molecules lack an important interaction that contributes to the stability of the MHC II ab-peptide complex. Consequently, the p9 residue(s) in such cases must be one that has a high stabilization potential. As such, DQ8cis andtrans prefer acidic residues for this anchor that form salt bridges with a76Arg, whereas DQ2cis and -trans prefer primarily aromatic residues because of the spaciousness of their p9 pocket that requires a residue that will have maximal Van der Waals interactions.
Epitopes within the InsB6-22 sequence
The core nonamers fitting into the respective antigenbinding grooves of the four DQ molecules, obtained after energy minimization, were aligned (Table 2 ). Besides the already-known core nonamer epitope of InsB13-21 for DQ8cis ( Supplementary Figure 1) , the other three HLA-DQ molecules conferring susceptibility to T1D also require the same core nonamer epitope InsB13-21 ( Figure 3 ). Molecular simulation limited to 1000 cycles showed that InsB8-16 may bind weakly to DQ2, but this was not verified by more extensive energy minimization cycles. The binding simulation of InsB13-21 to DQ2cis contrasts with earlier claims that the InsB9-23 peptide was unable to bind to DQ2cis. 33 Molecular simulation of InsB13-21 showed binding to both trans-molecules and DQ8cis. By contrast, DQ8trans accepts primarily aromatic and aliphatic residues at p1 and secondarily a glutamate Table 1 Anchoring motifs for antigenic peptide residues in the five pockets of the DQ2/8 cis-and trans-molecules Molecule/pocket p1 p4 p6 p7 p9 HLA-DQ8 homozygosity and heterozygosity in type 1 diabetes P Eerligh et al Figure 3 TCR view of pockets 1, 4 and 9 of selected HLA-DQ alleles. This is to show the molecular interactions, especially in the DQ2trans and DQ8trans, whose motifs have not been worked out experimentally. As all four alleles have identical residues from their b-chain participating in the formation of pocket 1, the character of this pocket is mostly determined by the a-chain residues participating in its formation. HLA-DQ residues are in Van der Waals surface representation colored according to atom charges (positive, blue; negative, red; neutral, gray), with a transparency function to view individual atoms. The anchor residues are shown in CPK form (atomic color codes for peptide residues: oxygen, red; nitrogen, blue; carbon, green; sulfur, yellow; hydrogen, white. For transparent HLA-DQ residues, same color code except for carbon, depicted in orange). The coordinates of HLA-DQ8cis were provided by Dr Kon Ho Lee, Laboratory of late Professor Don C Wiley, Harvard University. 
Abbreviations: HLA, human leukocyte antigen; Ins, insulin; T1D, type 1 diabetes. In the HLADQA1*0102/DQB1*0602 molecule a 'p3 shelf' (denoted here by the residue in italics) has been shown by binding studies. 33 Shown are the best alignments of core nonamer fitting into the respective antigen-binding grooves of both the susceptible and the protective molecules, obtained after energy minimization, and verified by binding (anchor residues in bold).
HLA-DQ8 homozygosity and heterozygosity in type 1 diabetes P Eerligh et al residue in this epitope, because of the presence of two arginines in the surface of the p1 pocket (a49 and 52) and the presence of a31Gln and a24His. The a31Gln residue facilitates accommodating glutamate in the p1 pocket of DQA1*0501 molecules. The other pockets of this complex can all accept the respective anchor residues without any conflicts; there are several favorable interactions between peptide anchor and DQ residues. The situation is more favorable in the case of DQ2trans, where all anchor residues of InsB13-21 fit well into their respective pockets. For DQ2cis, the relative weakness in binding InsB13-21 may arise from the combination of p4Tyr and p6Val, and to a lesser extent p7Cys, which are not readily preferred in the respective pockets.
Binding of the predicted InsB6-22 epitopes to various DQ-expressing BLCL Based on the energy minimization studies with the InsB6-22 peptide and the cis-and trans-molecules, epitopes within this insulin peptide were predicted to be favored by the cis-and trans-molecules (Table 2) as mentioned before. To examine the binding potential of these epitopes to various DQ-expressing cell lines, we performed binding studies in a cell-free peptide binding assay.
Only the peptide InsB13-21, which was predicted from the molecular simulation studies to bind all four DQ molecules, was indeed shown to bind all cell lines tested ( Figure 4 ). For DQ8 and DQ2/8 similar IC 50 values were calculated: 0.14 and 0.41 mM, respectively. The peptide InsB13-21 bound to DQ2 with an IC 50 of 0.98 mM, that is, with sevenfold lower affinity compared with DQ8. The peptide InsB8-16 did not bind to any DQ molecule tested (data not shown), while it was predicted from the molecular simulation studies as a weak DQ2 binder.
The lack of binding of peptide InsB6-14 to DQ2, DQ8 or either trans-molecules confirmed the selective binding to DQ6, as predicted by molecular modeling studies (IC 50 of 0.58 mM). We could confirm earlier reports that InsB6-14, as well as InsB12-20, bind to DQ6 with high affinity. 33 Thus, DQ2 and DQ8 cis-and trans-dimers bind a single and distinct epitope in the insulin B-chain compared with DQ6.
Peptide binding to trans-dimer-versus cis-dimer-expressing cell lines Thus far, the binding studies were performed with homozygous (expressing DQ cis-dimer molecules) and heterozygous BLCL (expressing DQ cis-and trans-dimer molecules). To confirm the selective specificity of peptide binding to the tested BLCL, we generated HEK293 transductants exclusively expressing DQ2 cis-, DQ8 cis-, DQ2 trans-or DQ8 trans-dimers. We verified peptide binding of the DQ2-specific peptide (EPRAP) and both DQ8-specific peptides (Syndecan and Thymosin b4) to the transductants. EPRAP bound to DQ2cis and, although with lower binding counts (counts per minute), to both trans-dimers ( Figure 5 ). Binding of EPRAP to DQ8cis was very weak. The DQ8-specific peptides Syndecan and Thymosin b4 bound to DQ8cis and both trans-dimers, but hardly to DQ2cis. These results corroborate the binding data obtained with the BLCL (Figure 1) .
With regard to insulin B-chain peptides, InsB13-21 bound to DQ2trans less than to DQ2cis, whereas binding to DQ8cis and -trans was comparable. As shown with BLCL, InsB6-14 hardly bound the cis-and trans-dimers as compared with binding to DQ6 (Supplementary Figure 3) . Although we cannot explain the observed reduced binding of InsB13-21 to DQ2trans, the overall data are in concordance with the observed binding of the InsB peptides to the BLCL.
Antigen-specific T-cell line and clones
An insulin B-chain-specific T-cell line was isolated from an HLA-DQ8 homozygous T1D patient upon restimulation of the freshly isolated peripheral blood mononuclear cells (PBMC) proved to be HLA-DQ8 restricted. Only (partly) DQ8-matched BLCL were able to stimulate the T cells in the presence of medium or the InsB6-22 peptide (Supplementary Figure 2) in a concentration-dependent manner. The response of the T-cell line was not due to HLA-DQ8 homozygosity and heterozygosity in type 1 diabetes P Eerligh et al DR4 expression, as DR4 þ DQ8 À BLCL were unable to induce a T-cell response. Furthermore, DQ-mismatched BLCL were unable to induce proliferation of the T-cell line (data not shown). Cytokine production of two T-cell clones derived from this line by cloning with either DQ8 homozygous, autologous APC or HLA-DQ2/8 or -DQ6/ 8 heterozygous allogenic APC was investigated in the presence of medium alone or InsB6-22 and a panel of APCs (BLCL) expressing DQ8 (DQ8/8, DQ6/8 and DQ2/8) (Figure 6 ). Antigen-specific stimulation of the T-cell clone with homozygous DQ8 APC resulted in high cytokine production of interferon (IFN)-g and interleukin (IL)-10 (52.7±17.8 and 164.0±22.1 spots, respectively) compared with heterozygous APCs that did not induce cytokine production by the T cells. In contrast, antigeninduced cytokine production and proliferation were completely reversed when insulin-specific T cells were cloned after stimulation with DQ6/8 heterozygous APCs. IFN-g production was absent, whereas in the presence of the homozygous DQ8/8 or the heterozygous DQ6/8 APC, production of IL-10 was observed (69.3±6.5 and 26.0±3.6 spots, respectively; Supplementary Table 2 ). The cytokine production profile indicated that the DQ8-restricted T cells cloned with DQ8 homozygous APC display a proinflammatory phenotype when stimulated by DQ8 homozygous APC-presenting HLA-DQ8 homozygosity and heterozygosity in type 1 diabetes P Eerligh et al insulin, whereas T cells cloned with DQ8/6 heterozygous APC display an anti-inflammatory phenotype, regardless of the HLA-DQ genotype of the insulin-presenting APCs.
T-cell proliferative responses to InsB6-22 were determined by HLA-DQ homozygosity (Supplementary Table  2 ). Proliferation of the DQ8/8-generated T-cell clone in response to InsB6-22 was observed in the presence of the homozygous DQ8/8 APC (si ¼ 7.8), whereas no proliferative response was seen with the heterozygous DQ6/8 and DQ2/8 APCs. On the contrary, the DQ6/8-generated T-cell clone did not proliferate to its cognate antigen presented by either DQ8 homo-or heterozygous APC.
Materials and methods

Peptide synthesis
Peptides were synthesized according to standard fluorenylmethoxycarbonyl chemistry using a SyroII peptide synthesizer (MultiSynTech, Witten, Germany). The integrity of the peptides was checked using reversed phase-high-performance liquid chromatography and mass spectrometry. The following peptides have been used in the binding studies as biotinylated peptides: EPRAP: EEPRAPWIEQEGPEYWDQE; Syndecan, LPDD EDVVGPGQESDDE; and Thymosin b4, EDKPDMAEIE KFDK. Nonamer peptides were synthesized with two overhanging alanines both N and C terminally for binding in the DQ binding groove.
B-cell lines
Human HLA-DQ2/2 (Ducaf), HLA-DQ8/8 (Boleth), HLA-DQ2/8 (FK and B64), HLA-DQ6/6 (LD2B) and DQÀ/À (721.82) expressing Epstein-Barr virus-transformed BLCL generated from B cells of healthy individuals were used in all binding experiments. BLCL were cultured at 37 1C in 5% CO 2 , in a humidified atmosphere in medium (Iscove's modified Dulbecco's medium; Gibco BRL, Paisely, UK) containing 10% heat-inactivated fetal calf serum supplemented with L-glutamine.
Lentivirus production and transduction
Third-generation lentiviruses were produced following standard procedures. 34 Briefly, lentiviral vectors (pRRL-CMV-GOI-GFP/puro) containing our gene of interest (DQA1*0501, DQA1*0301, DQB1*0302, DQB1*0201) were co-transfected with 'helper' plasmids (encoding HIV-1 gag-pol; HIV-1 rev and HIV-1 vesicular stomatitis virus G envelope) into 293T cells. Viruses containing supernatants were harvested after 48 and 72 h, passed through a 0.45 mm filter and stored until use at À80 1C. Virus titers were estimated by enzyme-linked immunosorbent assay for HIV p24 level (ZeptoMetrix Corp., Buffalo, NY, USA). For co-transductions of HEK293 cells, viral supernatants were added to fresh media supplemented with 8 mg ml
À1
Polybrene (Sigma, Zwijndrecht, the Netherlands), and cells were incubated overnight. Viral supernatants were removed, cells were washed twice and cultured in normal medium as described above. Finally, transduced cells were single-cell sorted to obtain HLA-DQ8 homozygosity and heterozygosity in type 1 diabetes P Eerligh et al clones with high DQ expression as measured by FACS analysis.
Whole-cell peptide-binding assay
To show binding of the InsB6-22 and InsB9-23 peptides to homozygous and heterozygous HLA-DQ-expressing cells, whole-cell peptide-binding assay were performed as the cell-free peptide binding assay resulted in too much a specific binding. The whole cell peptide-binding protocol has been described before. 23 Briefly, 1 Â 10 6 BLCL functioning as APCs were washed and incubated with a polyclonal antibody blocking HLA-DR (B8.11.2) for 1 h at 4 1C. Cells were washed and fixed with paraformaldehyde. Subsequently, after washing cells were incubated with 10 mM biotinylated peptide in citrate-phosphate buffer for 20 h at 37 1C. After washing, cells were lysed in NP-40 lysis buffer (containing 50 mM Tris, 150 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 10 mM iodoacetamide and protease inhibitors (Complete protease inhibitor mix; Roche Diagnostics, Mannheim, Germany), pH 7.4) for 1 h at 4 1C. To remove nuclei and insoluble materials, lysates were centrifuged at 3500 r.p.m. for 20 min at 4 1C. The lysates were plated onto 96-well plates pre-coated with the pan-DQ antibody (SPV-L3, 10 mg ml
À1
) and blocked with phosphate-buffered saline (PBS)/1% bovine serum albumin. After the addition of 100 ml NP-40 lysis buffer and overnight incubation at 4 1C, cells were washed and Europium-labeled streptavidin was added in the presence of 100 ml assay buffer (Wallac Oy, Turku, Finland) for 45 min at room temperature. Cells were washed and Enhancement buffer (Wallac DELFIA) was added to the wells. After an incubation period of 15 min at room temperature, fluorescence was measured. IC 50 values were calculated based on the observed binding of the tested peptides against the fixed concentration reporter peptide; the concentration of tested peptide required for half-maximal inhibition of binding of the reporter peptide indicate the IC 50 value.
HLA-DQ-insulin peptide homology modeling
Homology modeling of the complexes between the four HLA-DQ alleles obtained in the DQ2/8 heterozygous state and the insulin B-chain peptides was performed as described previously, with certain important modifications. 24, 35 The recently determined crystal structures of DQ2cis (DQA1*0501-DQB1*0201) 29 and DQ8cis (DQA1*0301-DQB1*0302) 25 were used as base molecules. The program Quanta (Accelrys, San Diego, CA, USA) was used to obtain a complete structure by providing the missing amino-acid residues from the crystal structure (for example, b105-112), as well as missing atoms from certain residues. The HLA-DQ trans-molecules were obtained by aligning the Ca of DQ2 and DQ8 in the bpleated sheet regions of the a1b1 domains of these molecules. Using the appropriate combinations, we obtained base structures for the DQA1*0501-DQB1*0302 (DQ8trans) and DQA1*0301-DQB1*0201 (DQ2trans). In all three cases (DQ8trans, DQ2cis and DQ2trans), the antigenic peptide coordinates of the DQ8cis-InsB11-23 complex were used, as they contained no proline residues, and had all canonical anchor residues in the respective pockets. Energy minimization of each respective complex was carried out at pH 5.4 via the program Discover of Accelrys on Silicon Graphics Fuel and Indigo instruments (Fremont, CA, USA), using 1000 cycles of the steepest gradient approach, followed by 1000 cycles of the conjugate gradient approach. In the case of DQ2cis allele, it was necessary to extend the latter part to 2000 cycles to obtain an unambiguous minimization value. As a safeguard measure, the conjugate gradient step was extended to 5000 cycles for all three alleles (DQ2cis, DQ2trans, DQ8trans), without altering the energy order of the minimized structures. A similar procedure for the crystal structure of the DQ8cis-InsB13-21 complex did not show any serious deviations from the determined crystal structure. 24, 25 All structures were examined for atomic clashes via the Discover program. The two generated HLA-DQ trans-molecules were examined in detail to have a physicochemical characterization of the possible anchor residues in their respective pockets. All possible sequences of 13 residues from human InsB6-22 were successively fitted into the groove of each HLA-DQ molecule in the register p2-p11, to determine the ones resulting in the least energy, after the energy minimization process. Graphical representations were performed via the WebLabViewer program (version 3.5) of Accelrys. The minimized structure thus obtained has the peptide in a polyproline II helical conformation as expected of all peptides bound to MHC II molecules. The numbering of the residues in the amino-acid sequences of the DQA and DQB molecules was carried out according to Bondinas et al., 32 as it ensures structural equivalence across MHC class II loci within the same and throughout different species. All three modeled structures will be deposited in the Protein Data Bank.
Cell-free peptide-binding assays
To examine binding of the shorter InsB6-22-derived peptides, a cell-free peptide binding assay was performed. For the homozygous and heterozygous EpsteinBarr virus-transformed BLCL, this assay was based on competition between a biotinylated reporter peptide and the peptide of interest. The binding assay with the lentiviral-transduced cells was based on direct binding of biotinylated peptides of interest. FluoroNunc 96-well plates were coated with the pan-DQ-antibody (SPV-L3) at a concentration of 10 mg ml À1 in 100 ml carbonate buffer (50 mM Na 2 CO 3 , 50 mM NaHCO 3 , pH 9.2) per well for 2 h at 37 1C. Plates were washed with PBS/0.05% Tween 20 and subsequently blocked with PBS/1% bovine serum albumin for 2 h at 37 1C. Epstein-Barr virus-transformed BLCL or lentiviral-transduced cell lines were checked for proper DQ expressing by FACS analysis using the pan DQ antibody SPV-L3. Cells were harvested by centrifugation (1500 r.p.m., 15 min), washed with PBS and lysed at 4 1C with lysis buffer (containing 50 mM Tris, 150 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 10 mM iodoacetamide and protease inhibitors (Complete protease inhibitor mix; Roche), pH 8.0) at a concentration of 4 Â 10 6 per ml. To remove nuclei and insoluble material, lysates were centrifuged at 3500 r.p.m. for 20 min at 4 1C. Lysates were mixed with an equal volume of PBS/1% bovine serum albumin and 100 ml was added to each SPV-L3-coated well. After an overnight incubation at 4 1C, plates were washed with PBS/0.05% Tween 20 and 50 ml binding buffer (containing 0.1% Tween 20, 0.1% Nonidet P-40, Complete protease inhibitor mix, 37.5 mM Na 2 H-PO 4 , adjusted to pH 5.4 with citric acid) was added to each well. Titration ranges of the tested peptides (from 0 to 300 mM) were prepared in 10% dimethyl sulfoxide containing a fixed concentration (0.6 mM) of biotinylated reporter peptide (KMRMATPLLMQAL (CLIP), a pan-DQ binder). Recently, an alternative CLIP sequence was discovered with a twofold lower IC 50 for DQ2. 36 However, to be consistent and obtain comparable results, the original CLIP peptide has been used in the binding assays. Subsequently, 50 ml of the peptide sample was applied to the SPV-L3/HLA-DQ-coated wells. After 48 h incubation at 4 1C, plates were washed with PBS/0.05% Tween 20 and 100 ml 0.1% Europium-streptavidin in assay buffer (containing 25 mM Tris-HCl, 75 mM NaCl, 0.5% bovine serum albumin, pH 7.5) was added to each well, followed by 45 min incubation while shaking. After washing with PBS/0.05% Tween 20, wells were incubated with 150 ml enhancement buffer (containing 15 mM 4,4,4-trifluoro-1-(2-naphthyl)-1,3-butanedione, 50 mM trin-octylphosphine oxide, 6.8 mM potassium hydrogen phthalate, 100 mM HAc, 0.1% Triton X-100) per well for 15 min. Plates were read using a time-resolved fluorometer (1234, Wallac). IC 50 values were calculated as mentioned before.
Patients, isolation and culture of InsB6-22-specific T lymphocytes After informed consent, peripheral blood was drawn from an 18-year-old Caucasian male diagnosed with T1D at the age of 8 years. Serum and PBMCs were investigated for autoantibodies and T-cell reactivity. PBMCs were isolated by Ficoll centrifugation and resuspended in culture medium (Iscove's modified Dulbecco's medium; Gibco BRL) containing 10% pooled human, heat-inactivated serum. PBMCs were tested in a lymphocyte stimulation assay using culture medium, IL-10 10% or 10 mg ml À1 InsB6-22 as described previously.
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For the generation of T-cell lines, 1.5 Â 10 5 freshly isolated PBMCs were incubated in culture medium containing 10 mg ml À1 InsB6-22 in round-bottomed 96-well plates (Costar, Cambridge, MA, USA). In the presence of InsB6-22 also 0.5% leuco A (Sigma-Aldrich, St Louis, MO, USA) was added to the T cells. The cells were incubated for 6 days and then expanded in culture medium containing 10% IL-2 (Promega, Madison, WI, USA). At day 14, 2 Â 10 5 T cells were restimulated with 1% phycoagglutinin-A (Pharmacia, Uppsala, Sweden) and 1 Â 10 6 feeder cells (mix of six different donor PBMCs irradiated with 3000 rad), and after an additional 3 days were expanded by adding 10% IL-2 to the culture medium. T-cell cultures were repeatedly split and after a further 10 days of incubation were frozen, tested or cloned directly by limiting dilution at a cell concentration of 0.3 cells per well. After limiting dilution, T-cell clones were generated in two ways: by restimulation in the presence of 10 mg ml À1 InsB6-22 peptide with homozygous DQ8/8 BLCL or with heterozygous DQ6/8 BLCL. Antigen specificity of T-cell lines and clones was tested by incubating 10 4 T cells with 5 Â 10 4 irradiated (3000 rad) partly HLA-DQ-matched PBMCs in the presence of InsB6-22. Cells were cultured in triplicates in medium alone, with 10 mg ml À1 InsB6-22 or IL-2 10% as positive control. Cultures were set up in a final volume of 150 ml culture medium well in flat-bottomed 96-well microculture plates (Greiner, Nü rtingen, Germany). After 3 days of incubation, 50 ml RPMI 1640 (Dutch modification; Gibco containing 0.5 mCi 3 H-thymidine (NEN Dupont, Boston, MA, USA) per well was added, and incubation was continued for 16 h. Cultures were then harvested onto glass fiber filters and 3 H-thymidine incorporation was measured by liquid scintillation counting.
T-cell proliferation assay
A T-cell proliferation assay was performed on T-cell clones derived from the T1D patient. 18 T-cell clones (1 Â 10 4 cells) and partly HLA-DQ-matched PBMCs isolated from healthy donors (5 Â 10 4 cells) in culture medium (Iscove's modified Dulbecco's medium; Gibco BRL) with 10% heat-inactivated human serum were seeded per well in flat-bottomed 96-well microculture plates (Greiner, Nü rtingen, Germany) and cultured for 3 days at 37 1C in 5% CO 2 , in a humidified atmosphere. Recombinant IL-2 (25 U ml À1 ; Genzyme, Cambridge, MA, USA) was added in separate wells to check viability of the T-cell clones. Proliferative responses were measured against the insulin peptide InsB6-22 (10 mg ml À1 ). In the final 16 h of culture, 0.5 mCi of 3 H-thymidine was added per well. After harvesting the cells on glass filters with an automated harvester, proliferation was determined by the measurement of Cytokine measurements A total of 10 4 T cells and 5 Â 10 4 matched PBMCs (irradiated 3000 rad) were incubated in a medium supplemented with 10% heat-inactivated human serum, or with the addition of 10 mg ml InsB6-22 peptide or phorbol 12-myristate 13-acetate 10 ng ml (Sigma, Zwijndrecht, the Netherlands) and ionomycin 1 mM (Calbiochem, La Jolla, CA, USA). Supernatants were harvested after 72 h incubation and tested for IFN-g or IL-10 by Elispot (Enzyme-Linked ImmunoSPOT, U-CyTech biosciences, Utrecht, the Netherlands).
Discussion
Our studies reveal distinct peptide binding characteristics of HLA-DQ cis-and trans-dimers, whereas the total repertoire of HLA molecules capable of presenting (autoantigenic) epitopes can determine the quality of the immune response. Furthermore, we provide a functional basis for the heterogeneity in genetic risk predisposition of HLA haplotypes in homozygous versus heterozygous individuals, pointing to the importance of the combinations of HLA haplotypes (that is, genotypes), rather than single haplotypes, to determine risk for disease. Finally, we offer a functional basis for a mechanism of dominant protection from disease, where HLA molecules associated with protection bind islet epitopes in a different, possibly competing, HLA-binding register, leading to 'epitope stealing' and conceivably diverting the immune response to islet epitopes otherwise dictated by disease-susceptible HLA molecules.
The HLA-DQ2-specific peptides indeed displayed the expected 25% binding in the DQ2/8 heterozygous cell line tested, implying selective binding to the HLA-DQ2 cis-dimer only, and providing a basis for the assumption that each DQA1-DQB1 combination contributes a quarter of the molecules on the cell surface of a heterozygous DQ2/8 cell line. However, peptides claimed to selectively bind to the HLA-DQ8 cis-dimer were shown to bind to at least one of the two trans-dimers expressed by HLA-DQ2/8 heterozygous cells. Yet, insulin B-chain peptides were capable of binding both DQ2 cis-and DQ8 cis-dimers as well as one or more trans-dimers to a highly similar extent. Peptide algorithms were defined predicting unique binding motifs for cis-and trans-dimer molecules of DQ2, DQ6 and DQ8 based on molecular simulation studies. Considerable differences between the peptide binding potential of the cis-dimers compared with the trans-dimers were defined. These may contribute to particular peptide binding repertoires distinguishing HLA-DQ2 and -DQ8 cis-and trans-dimers, and hence provide presentation of novel (islet) epitopes to the immune system. Yet, the peptide-binding studies with the InsB peptides showed binding of one peptide (InsB13-21) to all four cis-and trans-dimers. The molecular simulation and motif determining studies indicate that DQ2 has a preference for not only aliphatic residues (also Phe and Tyr) at positions 1 and 9 in the binding pocket of DQ2, but can also accommodate a negatively charged Glu (but not Asp) residue, present in the InsB chain peptide tested, at the same positions. In the context of autoimmunity, low binding affinities may still prove relevant; as such T-cell epitopes have been described that were proposed to result from poor thymic selection. A recent report showed that a diverse set of non-obese diabetic (NOD) anti-insulin T cells all recognize their epitope bound in the same register. Surprisingly, this register resulted in the poorest binding of peptide to IA g7 , implying that the association of autoimmunity with particular MHCII alleles may be due to poorer, rather than more favorable, binding of the critical self-epitopes, allowing T-cell escape from thymic deletion. 37 Our study on human T cells and MHC show that the same binding register of insulin peptides applies for different disease predisposing HLA-DQ molecules.
As predicted, the InsB6-14 peptide could only bind to DQ6. Altogether, the binding data, supported by the molecular simulation studies, show binding of the insulin B-chain peptide to both susceptible and protective T1D DQ-molecules via a different register.
The insulin B-chain peptide is a promiscuous peptide, as it is capable of binding molecules encoded by various HLA-DQ alleles associated with either susceptibility to or protection from T1D. Indeed, T-cell autoreactivity has been described against DR4-(0401), DR16-and DQ8-restricted insulin B-chain epitopes. 18, 22, 38, 39 Recent studies in NOD mice showed that the InsB12-20 and InsB13-21 peptides are the core nonamers for IA g7 binding and induced T-cell reactivity in the NOD mouse. 40, 41 Within InsB12-23 four binding registers exist capable of binding this molecule. Although in appearance IA g7 and HLA-DQ8 appear similar, yet there are subtle differences that may affect peptide binding and T-cell recognition. 42 IA g7 has a pH-dependent peptidebinding motif concerning pockets 6 and 9 arising largely from the presence of three histidines in proximity of these pockets (a68, b9 and b56), whereas DQ8 shows a higher binding affinity for peptides at endosomal pH, but no change in motif.
A notable aspect of the insulin B-chain peptide is the fact that in both T1D patients and NOD mice it harbors MHC class I-restricted CD8 T-cell epitopes within the sequence that we studied, in addition to CD4 T-cell eptiopes ll. 43, 44 One of the strongest epitopes for CD8 þ CTLs from T1D patients restricted to HLA-A2, the most common HLA-A allele in the Caucasian population, is the InsB10-18 peptide, which fits very well in the respective binding pocket. 44 It is thus very intriguing to postulate that for an abundant autoantigen in damaged b-cells such as insulin, HLA class I loading of processed peptides by cross-presentation would amplify the initial damage to b-cells by CD4 þ T cells. This overlap of MHC class I and class II epitopes, called 'combitope', potentially adds significance for immunotherapy. 45, 46 Notably, the InsB11-23-extended epitope has very hydrophobic solvent-contact residues (and thus potential TCR contact residues). From peptide extraction studies of DQ2cis, we know that a hydrophobic residue can be present at several positions within the binding core of DQ2cis. 30 These hydrophobic residues may act as TCR contact points, implying a rather restricted set of TCR-complementary determinant region recognition elements, as well as a non-canonical orientation for the TCRs, as described in multiple sclerosis. 47, 48 By contrast, the two HLA-DQ6-restricted 13-mer epitopes in the insulin B chain have several hydrophilic residues, rendering these peptides less likely to act as contact points of hydrophobic complementary determinant regions on pathogenic TCRs.
Thus far, few data have been available on human T-cell autoreactivity in the context of susceptible and protective DQ alleles. Here, we isolated and characterized human HLA-DQ8-restricted T-cell clones specific for the immunogenic b-cell autoantigen insulin B-chain peptide from an HLA-DQ8 homozygous juvenile patient with T1D. These insulin-specific T-cell clones produced high amounts IFN-g upon antigenic stimulation, which is consistent with a T h 1/T h 0-like cytokine profile and characteristic of diabetogenic T-cell clones in NOD mice. 45 Yet, T cells cloned in the presence of HLA-DQ8/6 heterozygous APC elicited a cytokine production profile completely shifted from a proinflammatory to an antiinflammatory profile when InsB peptide was presented by DQ6/DQ8 heterozygous donor APC. The T-cell clone was shown to be DQ8 restricted; therefore, a specific interaction between its TCR and DQ6 is unlikely. It could be argued that the binding of the insulin peptide to DQ6 modulates APC function and/or T-cell activation, modifying the quality of the autoimmune response from a proinflammatory IFN-g dominated to T h 2-or Tr1-like cytokine profile. Conceivably, a fourfold lower expression of HLA-DQ8 molecules compared with DQ8 homozygote cells may contribute to this immune diversion. We favor the alternative explanation that heterozygous DQ6/8 APC differentially activates CD4 þ T-cell populations compared with HLA-DQ8 homozygous APC. Peptides with binding potential to HLA-DQ8 molecules may preferentially bind to HLA-DQ6 molecules through a different binding register, thereby competing with, and conceivably modifying, DQ8-restricted T-cell reactivity, a mechanism referred to as 'determinant stealing'. 49, 50 This may explain the observed dominant protection of DQ6 in DQ8 þ individuals from T1D. Although we appreciate that T cells need to find suitable conditions for autoantigen presentation and activation in the target tissue, 51 this could not be assessed with our human T cells for practical and ethical reasons. Intriguingly, some insulin-specific CD4 þ T cells of NOD mice not recognizing protein when processed by APCs, escaped thymic control and caused diabetes, pointing to the relevance of processing, presentation as well as microenvironment, in addition to possessing the appropriate binding register and recognition motif of T-cell epitopes.
In conclusion, we propose that disease predisposition is determined by the nature and number of HLA-DQ molecules, their combined repertoire and context, and the functional consequences of their particular peptide motifs. Complementary HLA-DQ molecules may both synergize (for example, DQ2) or diminish (for example, DQ6) the functionality of disease-predisposing HLA molecules (for example, DQ8). In addition, the fact that all four T1D susceptibility-conferring DQ molecules bind InsB6-22 in the same 13-21 core nonamer 52 may allow the design of APLs and other tissue-specific therapeutics for prevention and cure of the disease.
